626 related articles for article (PubMed ID: 29650132)
81. Comparison of neoadjuvant and adjuvant chemotherapy for upper tract urothelial carcinoma in real-world practice: a multicenter retrospective study.
Takahashi K; Urabe F; Suhara Y; Nakano J; Yoshihara K; Goto Y; Sadakane I; Koike Y; Yata Y; Suzuki H; Kurawaki S; Miyajima K; Iwatani K; Imai Y; Sakanaka K; Nakazono M; Kurauchi T; Kayano S; Onuma H; Aikawa K; Yanagisawa T; Tashiro K; Tsuzuki S; Koike Y; Furuta A; Miki J; Kimura T
Jpn J Clin Oncol; 2023 Dec; 53(12):1208-1214. PubMed ID: 37647644
[TBL] [Abstract][Full Text] [Related]
82. [Treatments for advanced transitional cell carcinoma of the urinary tract: chemotherapy and operation].
Ozono S; Takashima K; Tabata S; Hirao Y; Okajima E
Hinyokika Kiyo; 1994 Oct; 40(10):931-8. PubMed ID: 7992711
[TBL] [Abstract][Full Text] [Related]
83. [Prognostic factors of survival in infiltrating urothelial bladder carcinoma. A retrospective study of 158 patients treated by radical cystectomy].
Thieblemont C; Fendler JP; Trillet-Lenoir V; Petris C; Chauvin F; Brunat-Mentigny M; Devaux Y; Devonec M; Gérard JP; Perrin P
Bull Cancer; 1996 Feb; 83(2):139-46. PubMed ID: 8652908
[TBL] [Abstract][Full Text] [Related]
84. Renal safety and efficacy of cisplatin-based chemotherapy in patients with a solitary kidney after nephroureterectomy for urothelial carcinoma of the upper urinary tract.
Cho KS; Joung JY; Seo HK; Cho IC; Chung HS; Chung J; Lee KH
Cancer Chemother Pharmacol; 2011 Apr; 67(4):769-74. PubMed ID: 20532510
[TBL] [Abstract][Full Text] [Related]
85. [Results of radical cystectomy for management of invasive bladder cancer with special reference to prognostic factors and quality of life depending on the type of urinary diversion].
Słojewski M
Ann Acad Med Stetin; 2000; 46():217-29. PubMed ID: 11712306
[TBL] [Abstract][Full Text] [Related]
86. Adjuvant chemotherapy in the management of pT3N0M0 transitional cell carcinoma of the upper urinary tract.
Lee SE; Byun SS; Park YH; Chang IH; Kim YJ; Hong SK
Urol Int; 2006; 77(1):22-6. PubMed ID: 16825811
[TBL] [Abstract][Full Text] [Related]
87. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) as neoadjuvant chemotherapy for patients with muscle-invasive transitional cell carcinoma of the bladder.
Blick C; Hall P; Pwint T; Al-Terkait F; Crew J; Powles T; Macaulay V; Munro N; Douglas D; Kilbey N; Protheroe A; Chester JD
Cancer; 2012 Aug; 118(16):3920-7. PubMed ID: 22614698
[TBL] [Abstract][Full Text] [Related]
88. The role of perioperative chemotherapy for upper tract urothelial carcinoma patients treated with radical nephroureterectomy.
Pinar U; Calleris G; Grobet-Jeandin E; Grande P; Benamran D; Thibault C; Gontero P; Rouprêt M; Seisen T
World J Urol; 2023 Nov; 41(11):3205-3230. PubMed ID: 36905443
[TBL] [Abstract][Full Text] [Related]
89. Effect of preoperative chemotherapy on survival of patients with upper urinary tract urothelial carcinoma clinically involving regional lymph nodes.
Kobayashi K; Saito T; Kitamura Y; Bilim V; Toba T; Kawasaki T; Hara N; Tanikawa T; Tomita Y
Int J Urol; 2016 Feb; 23(2):153-8. PubMed ID: 26607995
[TBL] [Abstract][Full Text] [Related]
90. Neoadjuvant chemotherapy for invasive bladder cancer.
Sonpavde G; Sternberg CN
Curr Urol Rep; 2012 Apr; 13(2):136-46. PubMed ID: 22314880
[TBL] [Abstract][Full Text] [Related]
91. Contemporary Trends of Systemic Neoadjuvant and Adjuvant Intravesical Chemotherapy in Patients With Upper Tract Urothelial Carcinomas Undergoing Minimally Invasive or Open Radical Nephroureterectomy: Analysis of US Claims on Perioperative Outcomes and Health Care Costs.
Del Giudice F; van Uem S; Li S; Vilson FL; Sciarra A; Salciccia S; Busetto GM; Maggi M; Tiberia L; Viscuso P; Canale V; Panebianco V; Pecoraro M; Ferro M; Moschini M; Krajewski W; D'Andrea D; Cacciamani GE; Mari A; Soria F; Porpiglia F; Fiori C; Amparore D; Checcucci E; Autorino R; De Berardinis E; Chung BI
Clin Genitourin Cancer; 2022 Apr; 20(2):198.e1-198.e9. PubMed ID: 35031226
[TBL] [Abstract][Full Text] [Related]
92. Induction and Maintenance Adjuvant Mitomycin C Topical Therapy for Upper Tract Urothelial Carcinoma: Tolerability and Intermediate Term Outcomes.
Metcalfe M; Wagenheim G; Xiao L; Papadopoulos J; Navai N; Davis JW; Karam JA; Kamat AM; Wood CG; Dinney CP; Matin SF
J Endourol; 2017 Sep; 31(9):946-953. PubMed ID: 28731777
[TBL] [Abstract][Full Text] [Related]
93. [Update on chemotherapy for bladder cancer. Update 2010].
Heck MM; Gschwend JE; Retz M
Urologe A; 2010 Oct; 49(10):1294-300. PubMed ID: 20859610
[TBL] [Abstract][Full Text] [Related]
94. Adjuvant chemotherapy for invasive bladder cancer: a 2013 updated systematic review and meta-analysis of randomized trials.
Leow JJ; Martin-Doyle W; Rajagopal PS; Patel CG; Anderson EM; Rothman AT; Cote RJ; Urun Y; Chang SL; Choueiri TK; Bellmunt J
Eur Urol; 2014 Jul; 66(1):42-54. PubMed ID: 24018020
[TBL] [Abstract][Full Text] [Related]
95. Oncologic outcomes obtained after neoadjuvant and adjuvant chemotherapy for the treatment of urothelial carcinomas of the upper urinary tract: a review.
Cordier J; Sonpavde G; Stief CG; Tilki D
World J Urol; 2013 Feb; 31(1):77-82. PubMed ID: 23053212
[TBL] [Abstract][Full Text] [Related]
96. Trends in utilization of neoadjuvant and adjuvant chemotherapy for muscle invasive bladder cancer.
McFerrin C; Davaro F; May A; Raza S; Siddiqui S; Hamilton Z
Investig Clin Urol; 2020 Nov; 61(6):565-572. PubMed ID: 32985142
[TBL] [Abstract][Full Text] [Related]
97. Treatment of muscle-invasive bladder cancer: A systematic review.
Chou R; Selph SS; Buckley DI; Gustafson KS; Griffin JC; Grusing SE; Gore JL
Cancer; 2016 Mar; 122(6):842-51. PubMed ID: 26773572
[TBL] [Abstract][Full Text] [Related]
98. Relationship between the number of lymph nodes dissected and prognosis in muscle-invasive bladder cancer in the era of neoadjuvant chemotherapy.
Tochigi K; Nagayama J; Bando S; Ishiyama A; Yuba T; Yuguchi Y; Matsui H; Hattori K; Gotoh M
Int J Urol; 2022 Nov; 29(11):1264-1270. PubMed ID: 35858759
[TBL] [Abstract][Full Text] [Related]
99. Changes in renal function following nephroureterectomy may affect the use of perioperative chemotherapy.
Kaag MG; O'Malley RL; O'Malley P; Godoy G; Chen M; Smaldone MC; Hrebinko RL; Raman JD; Bochner B; Dalbagni G; Stifelman MD; Taneja SS; Huang WC
Eur Urol; 2010 Oct; 58(4):581-7. PubMed ID: 20619530
[TBL] [Abstract][Full Text] [Related]
100. Integrating perioperative chemotherapy into the treatment of muscle-invasive bladder cancer: strategy versus reality.
Donat SM
J Natl Compr Canc Netw; 2009 Jan; 7(1):40-7. PubMed ID: 19176204
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
